Drug Profile
Ebola virus vaccine - Novavax
Alternative Names: Ebola virus recombinant glycoprotein nanoparticle vaccine; EBOV-GP Vaccine; Recombinant Ebola glycoprotein vaccine; Recombinant Ebola GP vaccineLatest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Novavax
- Class Glycoproteins; Recombinant proteins; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ebola virus infections
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for phase-I development in Ebola-virus-infections(Prevention) in Australia (IM, Injection)
- 28 Nov 2019 Ebola virus vaccine is still in phase I development for Ebola virus infection (Prevention) in Australia (Novavax pipeline, November 2019)
- 23 Jul 2015 Final immunogenicity data from a phase I trial in Ebola virus infections released by Novavax